glucagon receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-02-25. Numbers and descriptions here follow the published literature rather than marketing material.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
临床研究通常测量体重、腰围、空腹血糖、糖化血红蛋白和血脂，并记录不良事件。药代动力学评估关注浓度-时间曲线，药效动力学评估关注代谢标志物变化。体重下降由能量摄入减少、能量消耗变化和脂肪组织重塑共同造成，具体权重仍不明确。研究之间的终点定义和随访时长差异使横向比较复杂。
瑞他鲁肽同时激活GLP-1受体、GIP受体和胰高血糖素受体，这三者均属于B类G蛋白偶联受体。受体激活后主要经cAMP信号通路传递效应。GLP-1成分与食欲抑制和胃排空延缓相关，GIP成分影响脂肪组织与胰岛素分泌，胰高血糖素成分则促进肝糖输出和能量消耗。各受体贡献的相对比例在人体中尚未完全量化。
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
该化合物处于临床试验阶段，尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录，完整数据仍在逐步披露。关于长期疗效与安全性的判断，需要等待规模更大、随访更久的研究结果，目前不宜对最终结论作出预判。
retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。
== Background == An estimated 50% of oxidoreductases catalyze the transfer of a hydride using the nicotinamide adenine dinucleotide cofactor NAD(P). Nicotinamide adenine dinucleotide phosphate (NADPH) is used in anabolic reactions while nicotinamide adenine dinucleotide (NAD) is used in catabolic reactions. In the field of biocatalysis, NAD(P)-dependent oxidoreductases are widely used for the production of chiral alcohols, amines, and other valuable compounds. Yet the reduced forms of the cofactor, NADH and NADPH, needed for the catalysis, is too expensive to be used in stoichiometric amounts. Therefore a cofactor recycling system is usually employed.
=== Research applications === Polyphenol oxidases (PPOs): These include both catechol oxidases and tyrosinases. In additional to research, PPOs have also found applications as biocatalysts. Cystatins are proteins that inhibit cysteine proteases. Research are ongoing to evaluate the potential of using cystatins in crop protection to control herbivorous pests and pathogens.
=== Amphibians === Plethodontid salamanders and chameleons have evolved a harpoon-like tongue to catch insects. The Neotropical poison dart frog and the Mantella of Madagascar have independently developed similar mechanisms for obtaining alkaloids from a diet of mites and storing the toxic chemicals in skin glands. They have also independently evolved similar bright skin colors that warn predators of their toxicity (by the opposite of crypsis, namely aposematism). Caecilians are lissamphibians that secondarily lost their limbs, superficially resembling snakes and legless lizards. Oldest known tetrapods (semi-aquatic Ichthyostegalia) resembled giant salamanders (body plan, lifestyle), though they are considered to be only distantly related.
=== Newborn screening === Several countries test all newborns for SCID as a part of routine newborn screening. A measure using real-time quantitative PCR of the blood concentration of T-cell receptor excision circles (TRECs), which are reduced in SCID, is the method used to screen all U.S. newborns for SCID. As of September 2022, the known percentage of newborns screened has increased throughout the world with 100% in the United States, 100% in Australia, 78% in Europe, 32% in Latin America, 26% in the Middle East and North Africa, 13% in Asia-Pacific, and 0% in Central America. The introduction of newborn screenings and genetic testing in many countries has allowed early detection and treatment before the development of severe infections, which progressively improved the five-year survival rate for newborns with SCID to around 90%.
Sources: en.wikipedia.org
=== Industrial processes === Check valves are used in many fluid systems such as those in chemical and power plants, and in many other industrial processes. Typical applications in the nuclear industry are feed water control systems, dump lines, make-up water, miscellaneous process systems, N2 systems, and monitoring and sampling systems. In aircraft and aerospace, check valves are used where high vibration, large temperature extremes and corrosive fluids are present. For example, spacecraft and launch vehicle propulsion propellant control for reaction control systems (RCS) and Attitude Control Systems (ACS) and aircraft hydraulic systems. Check valves are also often used when multiple gases are mixed into one gas stream. A check valve is installed on each of the individual gas streams to prevent mixing of the gases in the original source. For example, if a fuel and an oxidizer are to be mixed, then check valves will normally be used on both the fuel and oxidizer sources to ensure that the original gas cylinders remain pure and therefore nonflammable. In 2010, NASA's Jet Propulsion Laboratory slightly modified a simple check valve design with the intention to store liquid samples indicative to life on Mars in separate reservoirs of the device without fear of cross contamination.
Antibacterials are used to treat bacterial infections. Antibiotics are classified generally as beta-lactams, macrolides, quinolones, tetracyclines or aminoglycosides. Their classification within these categories depends on their antimicrobial spectra, pharmacodynamics and chemical composition. Prolonged use of certain antibacterials can decrease the number of enteric bacteria, which may have a negative impact on health. Consumption of probiotics and healthy eating may help to replace destroyed gut flora. Stool transplants may be considered however for patients who are having difficulty recovering from prolonged antibiotic treatment, such as recurrent Clostridioides difficile infections. The discovery, development and use of antibacterials during the 20th century have reduced mortality from bacterial infections. The antibiotic era began with the therapeutic application of sulfonamide drugs in 1936, followed by a "golden" period of discovery from about 1945 to 1970, when a number of structurally diverse and highly effective agents were discovered and developed. Since 1980, the introduction of new antimicrobial agents for clinical use has declined, in part because of the enormous expense of developing and testing new drugs. In parallel, there has been an alarming increase in antimicrobial resistance of bacteria, fungi, parasites and some viruses to multiple existing agents. Antibacterials are among the most commonly used and misused drugs by physicians, for example, in viral respiratory tract infections.
The newer drugs have a better bioavailability as they are not charged and have a non-ionic interaction to the S1 pocket. Rivaroxaban During the SAR development of rivaroxaban, researchers realized that adding a 5-chlorothiophene-2-carboxamide group to the oxazolidonine core could increase the potency by 200 fold, which had previously been too weak for medical use. In addition to this discovery, a clear preference for the (S)-configuration was confirmed. This compound had a promising pharmacokinetical profile and did not contain a highly basic amidine group, but that had previously been considered important for the interaction with the S1 pocket. These findings lead to extensive SAR (structure-activity relationship) researches. During the SAR testing, R1 was defined as the most important group for potency. Pyrrolidinone was the first R1 functional group to significantly increase the potency but further researches revealed even higher potency with a morpholinone group instead. Groups R2 and R3 had hydrogen or fluorine attached and it was quickly assessed that having hydrogen resulted in highest potency. Groups R2 and R3 were then substituted for various groups, which were all less potent than the hydrogen, so hydrogen was the final result. As the chlorothiophene moiety had an inadequate water solubility, substituting it with another group was attempted but was unsuccessful. The chlorothiophene moiety binds to Tyr-228 at the bottom of the S1 pocket, making it a key factor regarding binding to FXa. Rivaroxaban has both high affinity and good bioavailability.
A dismissal for redundancy means that a job is no longer economically necessary for an employer's operations. To ensure the power of dismissal is not misused, the law attempts to ensure that the social costs of unemployment and dislocation are factored into the employer's decisions. Under the Fair Work Act 2009 section 531(2), employers must consult with unions if they contemplate that 15 or more jobs could be redundant, and under section 530 the employer must also give written notice to Centrelink of any proposals. The goal of the law is to avoid job losses, and so under section 531(3) the employer must consult unions on proposals on "measures to avert or minimise the proposed dismissals", alternative employment or mitigating adverse effects of proposed redundancies. If redundancies must take place, the National Employment Standard in section 119 requires minimum redundancy payments of at least 4 weeks' pay for employees that have worked over 1 year to 16 weeks' pay for people with at least 9 years' work, while those over 10 years' work may take advantage of long service leave and redundancy pay. However, employees can not take redundancy if they have been offered an acceptable alternative job. There are also a series of arbitrary exceptions to redundancy rights. Employees of employers with under 15 staff get nothing, on the theory that small businesses need protection more than workers. Casual, trainee and weekly fixed term employees are also excluded from protection, even though this means around 22% of the Australian workforce.
=== Cancer === Meta-analyses have been performed to examine the association between NQO1 polymorphism and increased cancer risk. The results from some of these analyses have been summarized in the table below:
Sources: en.wikipedia.org
On June 16, 2001, Sierra canceled the Dreamcast port of Half-Life, citing "changing market conditions". A late build of the Dreamcast version eventually leaked online, featuring complete versions of Half-Life and Blue Shift. Blue Shift and the High Definition pack were initially absent from the launch of Valve's content delivery system Steam in September 2003, despite the presence of both Half-Life and Opposing Force on the system. The game was released on Steam on August 29, 2005, along with the High Definition Pack. Blue Shift was also published as part of Sierra's Half-Life: Generation compilation in 2002, and as part of Valve and Electronic Arts' Half-Life 1: Anthology on September 26, 2005.
=== Ecohydrology === Ecohydrology is concerned with the interaction between ecosystems and water cycling, from measuring the small scale drainage of water into soil to tracking the broad movements of water evaporating from trees. Because deuterium acts as a conservative tracer, it works well for tracking water movement through plants and ecosystems. Though water movement in single-process phenomena such as evaporation is relatively simple to track, many systems (e.g. cloud forests) in the environment have multiple sources, and tracking water movement becomes more complicated. Isotope spiking can also be done to determine water transport through soil and into plants by injecting deuterated water directly into the ground. Stable isotope analysis of xylem water can be used to follow the movement of water from soil into the plants and therefore provide a record of the depth of water acquisition. An advantage to using xylem water is that in theory, the HIC should directly reflect the input water without being affected by leaf transpiration. For example, Dawson and Ehleringer used this approach to determine whether trees that grow next to streams are using the surface waters from that stream. Water from the surface would have the same isotopic composition as the stream, while water from farther below in the ground would be from past precipitation inputs. In this case, younger trees had a xylem water isotopic composition very close to the adjacent stream and likely used surface waters to get established.
As for the Basque Country, Rodríguez Zapatero announced shortly after having rejected on February 1, 2005, in the Congress of Deputies – with the support of the PP – the "Ibarretxe Plan", that he was willing to "dialogue" with ETA to put an end to terrorism. Almost a year later, on March 22, 2006, ETA announced a "permanent ceasefire" and that it would talk with the government about the "end of violence" if in parallel a "table of parties" was formed that would include the outlawed Batasuna. The PP's response was to accuse the government of having unilaterally broken the Antiterrorist Pact of 2000 and then subjected it to intense harassment both in the Cortes and in the streets, supporting the long series of demonstrations against the "surrender" to ETA called by the Association of Victims of Terrorism.
==== Thin-client ==== A thin-client LIMS is a more modern architecture which offers full application functionality accessed through a device's web browser. The actual LIMS software resides on a server (host) which feeds and processes information without saving it to the user's hard disk. Any necessary changes, upgrades, and other modifications are handled by the entity hosting the server-side LIMS software, meaning all end-users see all changes made. To this end, a true thin-client LIMS will leave no "footprint" on the client's computer, and only the integrity of the web browser need be maintained by the user. The advantages of this system include significantly lower cost of ownership and fewer network and client-side maintenance expenses. However, this architecture has the disadvantage of requiring real-time server access, a need for increased network throughput, and slightly less functionality. A sort of hybrid architecture that incorporates the features of thin-client browser usage with a thick client installation exists in the form of a web-based LIMS. Some LIMS vendors are beginning to rent hosted, thin-client solutions as "software as a service" (SaaS). These solutions tend to be less configurable than on-premises solutions and are therefore considered for less demanding implementations such as laboratories with few users and limited sample processing volumes. Another implementation of the thin client architecture is the maintenance, warranty, and support (MSW) agreement.
Organic compounds introduced on Earth by interstellar dust particles can help to form complex molecules, thanks to their peculiar surface-catalytic activities. The RNA component uracil and related molecules, including xanthine, in the Murchison meteorite were likely formed extraterrestrially, as suggested by studies of 12C/13C isotopic ratios. NASA studies of meteorites suggest that all four DNA nucleobases (adenine, guanine and related organic molecules) have been formed in outer space. The cosmic dust permeating the universe contains complex organics ("amorphous organic solids with a mixed aromatic–aliphatic structure") that could be created rapidly by stars. Glycolaldehyde, a sugar molecule and RNA precursor, has been detected in regions of space including around protostars and on meteorites.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.